Aapro M, Bourke JP (2003) Rapid intravenous administration of granisetron prior to chemotherapy is not arythmogenic: results of a pilot study. Eur J Cancer 39:927–931

Article  PubMed  CAS  Google Scholar 

O'Brien BJ, Rusthoven J, Rocchi a et al (1993) Impact of chemotherapy-induced nausea and vomiting on patients' functional status and on costs: survey of five Canadian centers. Can Med Assoc J 149:296–302

Google Scholar 

Navari RM (2003) Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting-two new agents. J Support Oncol 1:89–103

PubMed  CAS  Google Scholar 

De Leon A (2006) Palonosetron (Aloxi): a second-generation 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting. Bayl Univ Med Cent Proc 19:413–416

Google Scholar 

Doherty KM (1999) Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs 3:113–119

PubMed  CAS  Google Scholar 

Jantunen IT, Kataja VV, Muhonen TT, Parviainen T (1996) Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol 37:502–504

Article  PubMed  CAS  Google Scholar 

Yavas O, Yazici M, Eren O, Boruban C, Artac M, Genc M (2008) The acute effect of tropisetron on ECG parameters in cancer patients. Support Care Cancer 16:1011–1015

Article  PubMed  Google Scholar 

Buyukavci M, Olgun Hi Ceviz N (2005) The effects of ondansetron ang granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol 28:201–204

Article  PubMed  CAS  Google Scholar 

Navari RM, Koeller JM (2003) Electrocariographic and cardiovascular effects of the 5-hydroxitryptamine 3 receptor antagonists. Ann Pharmocother 37:1276–1286

Article  CAS  Google Scholar 

Watanabe H, Hasegawa A, Shinozaki T et al (1995) Possible cardiac side effects of granisteron an entiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol 35:278–282

Article  PubMed  CAS  Google Scholar 

Kasinath NS, Malak O, Tetzlaff J (2003) Atrial fibriallation after ondansetron for the prevention and treatment of postoperative nausea and vomiting a case report. Can J Anaesth 50:229–231

Article  PubMed  Google Scholar 

Audhuy B, Cappelaere P, Martin M et al (1996) A double-blind, randomized comparison of the antiemetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 32A(5):807–813

PubMed  CAS  Google Scholar 

Ballard HS, Bottino G, Bottino J (1992) Ondansetron and chest pain. Lancet 340(8827):1107

Article  PubMed  CAS  Google Scholar 

Boike SC, Ilson B, Zariffa N et al (1997) Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health Syst Pharm 54(10):1172–1176

PubMed  CAS  Google Scholar 

Hunt TL, Cramer M, Shah A et al (1995) A double-blind placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J Clin Pharmocol 35(7):705–712

CAS  Google Scholar 

Hesketh P, Navari R, Grote T et al (1996) Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol 14(8):2242–2249

PubMed  CAS  Google Scholar 

Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473–2482

Article  PubMed  CAS  Google Scholar 

Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570–1577

Article  PubMed  CAS  Google Scholar 

Morganroth J (2007) Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther 81(1):108–113

Article  PubMed  CAS  Google Scholar 

Morganroth J (2001) Focus on issues in measuring and interpreting changes in the QTc interval duration. Eur Heart J 3:105–111

Article  Google Scholar 

Morganroth J (2007) Evaluation of the effect on cardiac repolarization (QTc interval) of oncologic drugs. Ernst Schering Res Found Workshop 59:171–184

Article  PubMed  Google Scholar 

Kris MG, Grunberg SM, Gralla RJ et al (1994) Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 12:1045–1049

PubMed  CAS  Google Scholar 

Lifsey DS, Gralla RJ, Clark RA, Kline RC (1993) Electrocardiographic changes with serotonin antagonist antiemetics:rate of occurrence and clinical relevance. Proc Am Soc Clin Oncol 12:463, abst 1611

Google Scholar 

Gialafos JE (1999) P-wave dispersion. Eur Heart J 20(4):317

Article  PubMed  CAS  Google Scholar 

Dilaveris PE, Gialafos EJ, Sideris SK, Theopistou AM, Andrikopoulos GK, Kyriakidis M, Gialafos JE et al (1998) Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation. Am Heart J 135:733–738

Article  PubMed  CAS  Google Scholar 

Dilaveris PE, Gialafos EJ, Andrikopoulos GK, Richter DJ, Papanikolaou V, Poralis K, Gialafos JE (2000) Clinical and electrocardiographic predictors of recurrent atrial fibrillation. Pacing Clin Electrophysiol 23:352–358

Article  PubMed  CAS  Google Scholar 

Bitzen A, Sternickel K, Lewalter T, Schwab JO, Yang A, Schrickel JW, Linhart M et al (2007) Automatic p wave analysis over 24 hours in patients with paroxysmal or persistent atrial fibrillation. Ann Noninvasive Electrocardiol 12:306–315

Article  PubMed  Google Scholar 

Bazzet HR (1920) An analysis of the time relations of electrocardiographs. Heart 7:353–370

Google Scholar 

Benedict CR, Arbogast R, Martin L, Patton L, Morrill B, Hahne W (1996) Single-blind study of the effects of intravenous dalasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 28:53–59

Article  PubMed  CAS  Google Scholar 

Gray GW, McLellan TM, Ducharme MB (1996) Granisetron shows no pro-arrhythmic effect in normal subjects during or after exercise in a hot environment. Aviat Space Environ Med 67(8):759–761

PubMed  CAS  Google Scholar 

Lofters WS, Pater JL, Zee B et al (1997) Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 15(8):2966–2973

PubMed  CAS  Google Scholar 

Kuryshev YA, Brown AM, Wang L, Benedict CR, Rampe D (2000) Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther 295(2):614–620

PubMed  CAS  Google Scholar